Assembly Biosciences Inc Net Assets
Assembly Biosciences Inc net assets. Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has net assets worth $305.65 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($330.83 Million) and total liabilities ($25.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ASMB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $305.65 Million |
| % of Total Assets | 92.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | 22.39% |
| 10-Year Change | 158.83% |
| Growth Volatility | 142.6 |
Net Assets of Assembly Biosciences Inc (2008–2025)
Net assets of Assembly Biosciences Inc from 2008 to 2025. This chart illustrates how Assembly Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See ASMB net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Assembly Biosciences Inc (2008–2025)
The table below shows the annual net assets of Assembly Biosciences Inc from 2008 to 2025. For live market cap and overall valuation, see ASMB stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $206.75 Million | +519.78% |
| 2024-12-31 | $33.36 Million | -18.83% |
| 2023-12-31 | $41.10 Million | -50.28% |
| 2022-12-31 | $82.66 Million | -51.07% |
| 2021-12-31 | $168.93 Million | -29.78% |
| 2020-12-31 | $240.58 Million | -11.95% |
| 2019-12-31 | $273.22 Million | +29.70% |
| 2018-12-31 | $210.65 Million | +86.22% |
| 2017-12-31 | $113.12 Million | +41.62% |
| 2016-12-31 | $79.88 Million | -32.73% |
| 2015-12-31 | $118.74 Million | +102.73% |
| 2014-12-31 | $58.57 Million | +139.12% |
| 2013-12-31 | $24.49 Million | +37.53% |
| 2012-12-31 | $17.81 Million | -48.43% |
| 2011-12-31 | $34.53 Million | +197.03% |
| 2010-12-31 | $11.63 Million | +187.00% |
| 2009-12-31 | $-13.36 Million | -41.30% |
| 2008-12-31 | $-9.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Assembly Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 81869267600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Assembly Biosciences Inc Net Assets Breakdown (December 2025)
Assembly Biosciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.00K | 0.01% |
| Other Comprehensive Income | $-41.00K | -0.02% |
| Other Components | $1.04 Billion | 502.45% |
| Total Equity | $206.75 Million | 100.00% |
Assembly Biosciences Inc Competitors by Market Cap
The table below lists competitors of Assembly Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genesco Inc
NYSE:GCO
|
$405.60 Million |
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
$405.85 Million |
|
Regal Partners Global Investments Limited
AU:RG1
|
$405.87 Million |
|
Voneseals Technology (Shanghai) Inc. A
SHE:301161
|
$405.98 Million |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
$405.55 Million |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
$405.49 Million |
|
Wolfspeed, Inc.
NASDAQ:WOLF
|
$405.48 Million |
|
Lendingtree Inc
NASDAQ:TREE
|
$405.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Assembly Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 33,359,000 to 206,751,000, a change of 173,392,000 (519.8%).
- Net loss of 6,122,000 reduced equity.
- New share issuances of 168,307,000 increased equity.
- Other comprehensive income increased equity by 170,000.
- Other factors increased equity by 11,037,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.12 Million | -2.96% |
| Share Issuances | $168.31 Million | +81.41% |
| Other Comprehensive Income | $170.00K | +0.08% |
| Other Changes | $11.04 Million | +5.34% |
| Total Change | $- | 519.78% |
Book Value vs Market Value Analysis
This analysis compares Assembly Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-112.12 | $19.92 | x |
| 2009-12-31 | $-150.13 | $19.92 | x |
| 2010-12-31 | $93.77 | $19.92 | x |
| 2011-12-31 | $179.60 | $19.92 | x |
| 2012-12-31 | $69.97 | $19.92 | x |
| 2013-12-31 | $63.15 | $19.92 | x |
| 2014-12-31 | $83.69 | $19.92 | x |
| 2015-12-31 | $75.63 | $19.92 | x |
| 2016-12-31 | $46.36 | $19.92 | x |
| 2017-12-31 | $63.73 | $19.92 | x |
| 2018-12-31 | $92.39 | $19.92 | x |
| 2019-12-31 | $77.88 | $19.92 | x |
| 2020-12-31 | $60.63 | $19.92 | x |
| 2021-12-31 | $46.84 | $19.92 | x |
| 2022-12-31 | $20.49 | $19.92 | x |
| 2023-12-31 | $8.98 | $19.92 | x |
| 2024-12-31 | $5.56 | $19.92 | x |
| 2025-12-31 | $18.44 | $19.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Assembly Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.47%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.25x
- Recent ROE (-2.96%) is above the historical average (-65.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.84 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.20 Million |
| 2010 | -131.52% | 0.00% | 0.00x | 1.26x | $-16.45 Million |
| 2011 | -99.46% | 0.00% | 0.00x | 1.07x | $-37.80 Million |
| 2012 | -139.19% | 0.00% | 0.00x | 1.15x | $-26.57 Million |
| 2013 | -79.22% | 0.00% | 0.00x | 1.11x | $-21.85 Million |
| 2014 | -40.62% | 0.00% | 0.00x | 1.22x | $-29.65 Million |
| 2015 | -23.96% | 0.00% | 0.00x | 1.13x | $-40.33 Million |
| 2016 | -55.41% | 0.00% | 0.00x | 1.23x | $-52.25 Million |
| 2017 | -37.84% | -474.66% | 0.05x | 1.50x | $-54.12 Million |
| 2018 | -43.08% | -613.02% | 0.06x | 1.27x | $-111.82 Million |
| 2019 | -35.73% | -611.63% | 0.05x | 1.27x | $-124.96 Million |
| 2020 | -25.83% | -78.57% | 0.28x | 1.18x | $-86.21 Million |
| 2021 | -76.87% | -2076.35% | 0.03x | 1.13x | $-146.75 Million |
| 2022 | -111.38% | 0.00% | 0.00x | 1.23x | $-100.34 Million |
| 2023 | -148.98% | -854.78% | 0.05x | 3.33x | $-65.34 Million |
| 2024 | -120.44% | -140.87% | 0.24x | 3.57x | $-43.51 Million |
| 2025 | -2.96% | -8.47% | 0.28x | 1.25x | $-26.80 Million |
Industry Comparison
This section compares Assembly Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Assembly Biosciences Inc (ASMB) | $305.65 Million | 0.00% | 0.08x | $405.58 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more